- Exclusive U.S. patent rights for computer-aided diagnosis (“CADx”) with breast CT secured through a global license with the University of California
- CADx planned as a post-market software upgrade, creating dual revenue streams via upgrade incentives and licensing
- Patent exclusivity paired with proprietary machine-learning reconstruction establishes a durable moat in dedicated breast imaging
The AI Integration Challenge in Medical Imaging
Artificial intelligence has long promised to revolutionize radiology, but most applications remain stuck between theoretical potential and real-world limitations. CADx systems can enhance detection, yet they face hurdles: lack of specialized datasets, workflow disruptions, and intellectual property barriers.
In breast imaging, the stakes are higher. Nearly half of screening patients present with dense breast tissue, where overlapping structures can mask cancers. General-purpose AI retrofits struggle to overcome these limitations. True innovation requires purpose-built platforms that integrate AI from the ground up.
Izotropic (CSE: IZO) (OTCQB: IZOZF) is addressing this head-on, securing exclusive rights to the only U.S. patent for CADx with breast CT, positioning its IzoView system as the first platform built for seamless AI integration in dedicated breast imaging.
Patent Acquisition Creates Strategic Differentiation
IzoView, Izotropic’s flagship 3D breast CT system, offers a powerful imaging alternative bridging the gap between DBT and MRI. The newly licensed CADx patent marks more than a technical addition; it creates clear separation from competitors.
CADx analyzes images to estimate malignancy likelihood, giving radiologists faster, more confident decision support. In breast imaging, CADx addresses the diagnostic gaps left by mammography, DBT, and MRI, whether it’s density masking cancers or overwhelming volumes of data.
The patent covers CADx specifically for breast CT. That technical specificity creates protection against competitors trying to bolt AI onto existing systems. Unlike generalized CADx adaptations, Izotropic’s exclusive license ensures only IzoView can legally integrate this capability into dedicated breast CT.
Phased Rollout Maximizes Market Potential
Izotropic is pursuing a phased commercialization strategy. IzoView will debut without CADx but with its proprietary machine-learning reconstruction algorithm, trained on 15 years of breast CT data, that enhances image quality at low radiation doses.
CADx will arrive as a post-market software upgrade, creating dual opportunities: early adopters gain integration incentives, while Izotropic establishes recurring revenue through software licensing. This approach allows the company to penetrate the market quickly, then layer on AI enhancements as regulatory approvals and workflow demand align.
Competitive Moat Through Integrated AI Architecture
The CADx patent complements Izotropic’s reconstruction algorithm, protected as a trade secret. Together, they form a multi-layered moat that competitors will find difficult to breach.
Most medical AI systems exist as standalone overlays, requiring extra hardware or workflow adjustments. IzoView avoids these pitfalls: both the platform and its AI were designed specifically for breast CT, ensuring seamless integration.
With CADx patent exclusivity blocking rival systems, and its reconstruction algorithm leveraging a dataset competitors cannot replicate, Izotropic has effectively locked down the high ground in breast CT AI.
Market Implications and Revenue Diversification
The patent’s commercial implications extend well beyond technical differentiation. In medical imaging, software upgrades increasingly drive growth, enabling providers to add functionality without costly equipment replacement.
For Izotropic, CADx unlocks recurring software licensing revenue that complements hardware sales. As IzoView’s installed base grows, this creates a compounding model of upfront system sales plus ongoing software monetization.
Exclusive CADx rights ensure IzoView is the only breast CT platform offering this level of AI integration, creating a sustainable competitive advantage as AI adoption accelerates across healthcare.
Investment Positioning
Izotropic’s CADx patent represents a pivotal milestone: it secures protected AI capabilities that extend the company’s existing technical leadership while creating software-driven revenue opportunities.
The commercialization strategy is pragmatic: launch first with IzoView’s core imaging strengths, then expand functionality with AI upgrades that enhance diagnostic accuracy and expand revenue per installation.
For investors, the combination of specialized hardware, protected AI software, and recurring revenue potential defines a compelling story. In an AI landscape where most competitors chase generalized solutions, Izotropic is carving out a defendable, first-mover position in one of the most challenging and valuable imaging domains: breast cancer detection.
For more information, visit the company’s website at www.IzoCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at ibn.fm/IZOZF
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.TechMediaWire.com
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
TechMediaWire
Los Angeles, CA
www.TechMediaWire.com
310.299.1717 Office
Editor@TechMediaWire.com
TechMediaWire is powered by IBN